These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21178026)

  • 21. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging.
    Yamada A; Hara T; Li F; Fujinaga Y; Ueda K; Kadoya M; Doi K
    Radiology; 2011 Sep; 260(3):727-33. PubMed ID: 21712472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Shiratori Y; Onozuka M; Moriyama N
    AJR Am J Roentgenol; 2010 Oct; 195(4):941-6. PubMed ID: 20858822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
    Kühn JP; Hegenscheid K; Siegmund W; Froehlich CP; Hosten N; Puls R
    AJR Am J Roentgenol; 2009 Nov; 193(5):1318-23. PubMed ID: 19843748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography?
    Reiner CS; Merkle EM; Bashir MR; Walle NL; Nazeer HK; Gupta RT
    AJR Am J Roentgenol; 2013 Jul; 201(1):W49-56. PubMed ID: 23789696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system--what is normal?
    Ringe KI; Husarik DB; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2011 Aug; 79(2):201-5. PubMed ID: 20347540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
    Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.
    Channual S; Tan N; Siripongsakun S; Lassman C; Lu DS; Raman SS
    AJR Am J Roentgenol; 2015 Sep; 205(3):546-53. PubMed ID: 26295640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate.
    Schmid-Tannwald C; Herrmann K; Oto A; Panteleon A; Reiser M; Zech C
    Acta Radiol; 2012 Nov; 53(9):961-5. PubMed ID: 23024179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
    Zizka J; Klzo L; Ferda J; Mrklovský M; Bukac J
    Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
    Kim MJ; Rhee HJ; Jeong HT
    AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
    Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
    J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors.
    Chernyak V; Kim J; Rozenblit AM; Mazzoriol F; Ricci Z
    J Magn Reson Imaging; 2011 Aug; 34(2):301-9. PubMed ID: 21608069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
    Esterson YB; Flusberg M; Oh S; Mazzariol F; Rozenblit AM; Chernyak V
    Clin Radiol; 2015 Jul; 70(7):723-9. PubMed ID: 25921617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
    Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
    AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium.
    Bashir MR; Castelli P; Davenport MS; Larson D; Marin D; Hussain HK; Jaffe TA
    Radiology; 2015 Jan; 274(1):141-8. PubMed ID: 25162310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.
    Ringe KI; Husarik DB; Sirlin CB; Merkle EM
    AJR Am J Roentgenol; 2010 Jul; 195(1):13-28. PubMed ID: 20566794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-body MRI with assessment of hepatic and extraabdominal enhancement after administration of gadoxetic acid for staging of rectal carcinoma.
    Huppertz A; Franiel T; Wagner M; Püttcher O; Wagner J; Rief M; Schwenke C; Hamm B; Strassburg J
    Acta Radiol; 2010 Oct; 51(8):842-50. PubMed ID: 20698804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal acquisition delay for dynamic contrast-enhanced MRI of hypervascular hepatocellular carcinoma.
    Goshima S; Kanematsu M; Kondo H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
    AJR Am J Roentgenol; 2009 Mar; 192(3):686-92. PubMed ID: 19234264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI.
    Kim B; Byun JH; Kim HJ; Won HJ; Kim SY; Shin YM; Kim PN
    Eur Radiol; 2016 Jan; 26(1):191-8. PubMed ID: 25933742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.